SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-025384
Filing Date
2022-11-17
Accepted
2022-11-17 16:14:56
Documents
13
Period of Report
2022-11-14
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dice-20221114.htm   iXBRL 8-K 71230
2 EX-3.1 dice-ex3_1.htm EX-3.1 393325
  Complete submission text file 0000950170-22-025384.txt   637355

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dice-20221114_lab.xml EX-101.LAB 14563
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dice-20221114.xsd EX-101.SCH 2493
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dice-20221114_pre.xml EX-101.PRE 10690
7 EXTRACTED XBRL INSTANCE DOCUMENT dice-20221114_htm.xml XML 5123
Mailing Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080
Business Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080 650-566-1402
DICE Therapeutics, Inc. (Filer) CIK: 0001645569 (see all company filings)

IRS No.: 472286244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40794 | Film No.: 221398520
SIC: 2834 Pharmaceutical Preparations